Literature DB >> 12709315

Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.

S Pukrittayakamee1, S Prakongpan, S Wanwimolruk, R Clemens, S Looareesuwan, N J White.   

Abstract

The effects of adding rifampin to quinine were assessed in adults with uncomplicated falciparum malaria. Patients were randomized to receive oral quinine either alone (n = 30) or in combination with rifampin (n = 29). Although parasite clearance times were shorter in the quinine-rifampin-treated patients (mean +/- standard deviation, 70 +/- 21 versus 82 +/- 18 h; P = 0.023), recrudescence rates were five times higher (n = 15 of 23; 65%) than those obtained with quinine alone (n = 3 of 25; 12%), P < 0.001. Patients receiving rifampin had significantly greater conversion of quinine to 3-hydroxyquinine and consequently considerably lower concentrations of quinine in their plasma after the second day of treatment (median area under the plasma drug concentration-time curve from day zero to day 7 = 11.7 versus 47.5 micro g/ml. day, P < 0.001). Rifampin significantly increases the metabolic clearance of quinine and thereby reduces cure rates. Rifampin should not be combined with quinine for the treatment of malaria, and the doses of quinine should probably be increased in patients who are already receiving rifampin treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709315      PMCID: PMC153304          DOI: 10.1128/AAC.47.5.1509-1513.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure.

Authors:  P Newton; D Keeratithakul; P Teja-Isavadharm; S Pukrittayakamee; D Kyle; N White
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jan-Feb       Impact factor: 2.184

2.  The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.

Authors:  R A Mirghani; U Hellgren; P A Westerberg; O Ericsson; L Bertilsson; L L Gustafsson
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

Review 3.  Delaying antimalarial drug resistance with combination chemotherapy.

Authors:  N J White
Journal:  Parassitologia       Date:  1999-09

4.  Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.

Authors:  W Ridtitid; M Wongnawa; W Mahatthanatrakul; P Chaipol; M Sunbhanich
Journal:  J Pharm Pharmacol       Date:  2000-10       Impact factor: 3.765

Review 5.  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1990       Impact factor: 2.184

6.  Inhibition of rodent malaria in mice by rifampicin.

Authors:  N E Alger; D T Spira; P H Silverman
Journal:  Nature       Date:  1970-07-25       Impact factor: 49.962

7.  In vivo and in vitro sensitivity of Falciparum malaria to quinine in Thai children.

Authors:  T Chongsuphajaisiddhi; A Sabcharoen; P Attanath
Journal:  Ann Trop Paediatr       Date:  1981-03

8.  Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria.

Authors:  S Pukrittayakamee; A Chantra; S Vanijanonta; R Clemens; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Antimalarial activity of rifampicin in vitro and in rodent models.

Authors:  M Strath; T Scott-Finnigan; M Gardner; D Williamson; I Wilson
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Mar-Apr       Impact factor: 2.184

10.  A circular DNA in malaria parasites encodes an RNA polymerase like that of prokaryotes and chloroplasts.

Authors:  M J Gardner; D H Williamson; R J Wilson
Journal:  Mol Biochem Parasitol       Date:  1991-01       Impact factor: 1.759

View more
  10 in total

1.  Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.

Authors:  Gregory A Deye; Montip Gettayacamin; Pranee Hansukjariya; Rawiwan Im-erbsin; Jetsumon Sattabongkot; Yarrow Rothstein; Louis Macareo; Susan Fracisco; Kent Bennett; Alan J Magill; Colin Ohrt
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).

Authors:  Jason M Fritzler; Guan Zhu
Journal:  J Antimicrob Chemother       Date:  2011-12-13       Impact factor: 5.790

3.  In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.

Authors:  Kasia Stepniewska; Walter R J Taylor; Mayfong Mayxay; Ric Price; Frank Smithuis; Jean-Paul Guthmann; Karen Barnes; Hla Yin Myint; Martin Adjuik; Piero Olliaro; Sasithon Pukrittayakamee; Sornchai Looareesuwan; Tran Tinh Hien; Jeremy Farrar; François Nosten; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria.

Authors:  S Pukrittayakamee; S Wanwimolruk; K Stepniewska; A Jantra; S Huyakorn; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 5.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

Review 6.  Tuberculosis and pharmacological interactions: A narrative review.

Authors:  Niccolò Riccardi; Diana Canetti; Paola Rodari; Giorgio Besozzi; Laura Saderi; Marco Dettori; Luigi R Codecasa; Giovanni Sotgiu
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-15

7.  Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.

Authors:  Kassoum Kayentao; Etienne A Guirou; Ogobara K Doumbo; Meera Venkatesan; Christopher V Plowe; Teresa L Parsons; Craig W Hendrix; Myaing M Nyunt
Journal:  Am J Trop Med Hyg       Date:  2014-01-13       Impact factor: 2.345

8.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

9.  Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Authors:  Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink
Journal:  Malar J       Date:  2014-09-13       Impact factor: 2.979

10.  Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection.

Authors:  Jayne Ellis; Prosperity C Eneh; Kenneth Ssebambulidde; Morris K Rutakingirwa; Mohammed Lamorde; Joshua Rhein; Fiona V Cresswell; David R Boulware; Melanie R Nicol
Journal:  Wellcome Open Res       Date:  2019-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.